Quantcast

BioPharma deal to begin rapid-AM

One of the best-known patent royalty securitizations, BioPharma Royalty Trust, will likely enter into early amortization following the third quarter trustee report due at the end of November.

Based on projections associated with Bristol-Myers Squibb Co.'s financial statements and reports, Standard & Poor's expects BioPharma's $57.15 million A' rated...

To continue reading, log in, register or subscribe below.Calendars are available to registered users of The Bond Buyer web site.
Please log in below with the credentials you established at the time of your subscription or when you set up a free trial. If you have never set up an account with The Bond Buyer, please click the "Free trial" link below to set up your account.

Already a subscriber? Log in here.

Please note you must now log in with your email address and password.

 

Upcoming Events

Already a subscriber? Log in here
Please note you must now log in with your email address and password.